Back to News
Market Impact: 0.4
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
Veradermics reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01. The extended-release oral minoxidil tablet is being developed for men with mild to moderate pattern hair loss; the report provided no numerical results or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
MANE0.65
More News
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Walmart’s Flipkart is quietly building a food delivery challenger in India
- Credit stress is threatening to unwind the AI bull. All eyes are on Oracle to hold the line
- LightStream stops accepting loan applications. Try these 6 lenders instead
- Ciena EVP DiPerna sells $308,865 in CIEN stock